| Size | Price | Stock | Qty |
|---|---|---|---|
| 15mg |
|
||
| 50g |
|
||
| 100g |
|
||
| 200g |
|
||
| Other Sizes |
| Targets |
m-Nifedipine targets L-type calcium channels, similar to its parent compound Nifedipine. As a dihydropyridine calcium channel blocker, it inhibits calcium influx into vascular smooth muscle cells, leading to vasodilation and reduced blood pressure. Its mechanism is identical to that of Nifedipine.
|
|---|---|
| ln Vitro |
m-Nifedipine serves as a potent calcium channel blocker. As an impurity of Nifedipine, it is expected to have similar calcium channel blocking activity. However, its primary use is as a reference standard for analytical method development and quality control rather than for pharmacological evaluation.
|
| ln Vivo |
m-Nifedipine is not used as a therapeutic agent. Its in vivo effects would be expected to be similar to Nifedipine, but it is not administered as a drug. Its use is confined to analytical and quality control applications as an impurity standard.
|
| Enzyme Assay |
In vitro assays for m-Nifedipine typically involve analytical method development using HPLC or LC-MS. The compound is used as a reference standard to identify and quantify the meta-nitro impurity in Nifedipine samples. Its retention time and mass spectrum are characterized for method validation. Calcium channel blocking activity can be assessed using patch-clamp electrophysiology if needed.
|
| Cell Assay |
For in vitro cell-based assays, m-Nifedipine is not typically used, as it is an impurity and not a pharmacological agent. It could be used to study its potential effects on calcium channels if necessary, but its primary role is as an analytical reference standard. Cell viability and other cellular effects are not typically assessed for this compound.
|
| Animal Protocol |
In vivo animal studies with m-Nifedipine are not typically performed, as it is an impurity and not a therapeutic candidate. Its use is confined to analytical and quality control applications. The compound is not intended for in vivo pharmacological evaluation.
|
| ADME/Pharmacokinetics |
m-Nifedipine (CAS: 21881-77-6) has a molecular weight of 346.33 g/mol and a molecular formula of C17H18N2O6. Appearance: solid powder. Purity: ≥95%. Synonyms: Nifedipine Impurity, meta-Nifedipine. Storage: -20°C. The compound is a positional isomer impurity of Nifedipine.
|
| Toxicity/Toxicokinetics |
m-Nifedipine is a research compound and is not approved for human therapeutic use. As an impurity standard, it is used in very small quantities and does not pose significant toxicity risks under normal handling. Standard laboratory safety precautions should be followed when handling the compound.
|
| References | |
| Additional Infomation |
m-Nifedipine is an impurity of Nifedipine, a dihydropyridine calcium channel blocker. It is used as a reference standard for analytical method development and quality control. It is not FDA-approved as a drug and is intended for research and analytical use only.
|
| Molecular Formula |
C₁₇H₁₈N₂O₆
|
|---|---|
| Molecular Weight |
346.33
|
| Exact Mass |
346.116
|
| CAS # |
21881-77-6
|
| PubChem CID |
89082
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
478.1±45.0 °C at 760 mmHg
|
| Flash Point |
242.9±28.7 °C
|
| Vapour Pressure |
0.0±1.2 mmHg at 25°C
|
| Index of Refraction |
1.559
|
| LogP |
2.97
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
25
|
| Complexity |
608
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
MCTRZKAKODSRLQ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C17H18N2O6/c1-9-13(16(20)24-3)15(14(10(2)18-9)17(21)25-4)11-6-5-7-12(8-11)19(22)23/h5-8,15,18H,1-4H3
|
| Chemical Name |
dimethyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
|
| Synonyms |
m-Nifedipine m Nifedipine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Ethanol : ~5 mg/mL (~14.44 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 0.5 mg/mL (1.44 mM) (saturation unknown) in 10% EtOH + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 5.0 mg/mL clear EtOH stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 0.5 mg/mL (1.44 mM) (saturation unknown) in 10% EtOH + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 5.0 mg/mL clear EtOH stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8874 mL | 14.4371 mL | 28.8742 mL | |
| 5 mM | 0.5775 mL | 2.8874 mL | 5.7748 mL | |
| 10 mM | 0.2887 mL | 1.4437 mL | 2.8874 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
